Submissions from 2026
Real-world outcomes of cladribine in people ≥55 years of age with multiple sclerosis., Kyle Smoot, Tamela Stuchiner, Tiffany Gervasi-Follmar, and Chiayi Chen
Submissions from 2024
Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder., Luka Vlahovic, Jamie McDonald, Jessica Hinman, Anna Tomczak, Christopher Lock, Chella A Palmer, Lawrence J Cook, Michael R Yeaman, Melinda K Burnett, Gayle K Deutsch, Lorene M Nelson, and May H Han
Submissions from 2023
Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study., Le H Hua, Amit Bar-Or, Stanley L Cohan, Fred D Lublin, Patricia K Coyle, Bruce Ac Cree, Xiangyi Meng, Wendy Su, Gina Mavrikis Cox, and Robert J Fox
Robot-Assisted Transcranial Doppler Versus Transthoracic Echocardiography for Right to Left Shunt Detection., Mark N Rubin, Ruchir Shah, Thomas Devlin, Teddy S Youn, Michael F Waters, John J Volpi, Aaron Stayman, Colleen Douville, Ted Lowenkopf, Georgios Tsivgoulis, and Andrei V Alexandrov
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)., Kyle Smoot, Horia Marginean, Tiffany Gervasi-Follmar, Chiayi Chen, Pavle Repovic, and Stanley Cohan
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM., Mitzi J Williams, Lilyana Amezcua, Angel Chinea, Stanley Cohan, Annette Okai, Darin T Okuda, Wendy Vargas, Nick Belviso, Ivan Božin, Xiaotong Jiang, James B Lewin, Jennifer Lyons, Changyu Shen, Sarah M England, and Nydjie Grimes
Submissions from 2022
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study., Helmut Butzkueven, Paul S Giacomini, Stanley Cohan, Tjalf Ziemssen, Daniel Sienkiewicz, Ying Zhang, Yvonne Geissbühler, Diego Silva, Davorka Tomic, Harald Kropshofer, and Maria Trojano
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis., Stanley Cohan, Ralph H B Benedict, Bruce A C Cree, John DeLuca, Le H Hua, and Jerold Chun
Advancing Care and Outcomes for African American Patients With Multiple Sclerosis., Annette F Okai, Annette M Howard, Mitzi J Williams, Justine Brink, Chiayi Chen, tamela stuchiner, Elizabeth Baraban, Grace Jeong, and Stanley Cohan
Submissions from 2021
Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison., Stanley Cohan, Jinender Kumar, Stella Arndorfer, Xuelian Zhu, Marko Zivkovic, and Tom Tencer
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)., Stanley L Cohan, Barry A Hendin, Anthony T Reder, Kyle Smoot, Robin Avila, Jason P Mendoza, and Bianca Weinstock-Guttman
Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis., Stanley Cohan, Tom Tencer, Stella Arndorfer, Xuelian Zhu, Marko Zivkovic, and Jinender Kumar
Healthcare utilization and cost outcomes for a multicenter first seizure and new onset epilepsy clinic., Emily R Hudson, Alexandra Lesko, Lindsay Lucas, Elizabeth Baraban, and Evan J Fertig
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination., Ludwig Kappos, Stanley Cohan, Douglas L Arnold, Randy R Robinson, Joan Holman, Sami Fam, Becky Parks, Shan Xiao, and Wanda Castro-Borrero
Predictors of Outcomes in Patients With Mild Ischemic Stroke Symptoms: MaRISS., Jose G Romano, Hannah Gardener, Iszet Campo-Bustillo, Yosef Khan, Sofie Tai, Nikesha Riley, Eric E Smith, Ralph L Sacco, Pooja Khatri, Heather M Alger, Brian Mac Grory, Deepak Gulati, Navdeep S Sangha, Jeffrey M Craig, Karin E Olds, Curtis G Benesch, Adam G Kelly, Scott S Brehaut, Amit C Kansara, Lee H Schwamm, and MaRISS Investigators
Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study., Kyle Smoot, Chiayi Chen, Tamela Stuchiner, Lindsay Lucas, Lois Grote, and Stanley Cohan
Submissions from 2020
Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article., Stanley Cohan, Elisabeth Lucassen, Kyle E Smoot, Justine Brink, and Chiayi Chen
Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study., Abhishek Pratap, Daniel Grant, Ashok Vegesna, Meghasyam Tummalacherla, Stanley Cohan, Chinmay Deshpande, Lara Mangravite, and Larsson Omberg
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND., P Repovic, Derrick Robertson, Kiren Kresa-Reahl, Stanley Cohan, Ray Su, Robin Avila, Irene Koulinska, and Jason P Mendoza
Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry., Tamela Stuchiner, Lindsay Lucas, Elizabeth Baraban, Kateri Spinelli, Chiayi Chen, Alden Smith, Lobat Hashemi, and Stanley Cohan
Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM., Mitzi J Williams, Lilyana Amezcua, Annette Okai, Darin T Okuda, Stanley Cohan, Ray Su, Becky Parks, Jason P Mendoza, James B Lewin, and Cynthia C Jones
Submissions from 2019
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy., Stanley Cohan, Keith Edwards, Lindsay Lucas, Tiffany Gervasi-Follmar, Judy O'Connor, Jessica Siuta, Vineetha Kamath, Lore Garten, Chiayi Chen, James Thomas, Kyle E Smoot, Kiren Kresa-Reahl, and Kateri Spinelli
Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis., Stanley Cohan, Elisabeth B Lucassen, Meghan C Romba, and Stefanie N Linch
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes., Jinny Min, Stanley Cohan, Enrique Alvarez, Jacob Sloane, J Theodore Phillips, Anneke van der Walt, Irene Koulinska, Fang Fang, Catherine Miller, and Andrew Chan
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study., Robert Zivadinov, Kiren Kresa-Reahl, Bianca Weinstock-Guttman, Keith Edwards, Chakkarin Burudpakdee, Niels Bergsland, Michael G Dwyer, Bhupendra Khatri, Karthinathan Thangavelu, Jeffrey Chavin, Matt Mandel, and Stanley Cohan
Submissions from 2018
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study., Ralph Hb Benedict, Stanley Cohan, Sharon G Lynch, Katherine Riester, Ping Wang, Wanda Castro-Borrero, Jacob Elkins, and Guido Sabatella
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study., Sophie Cleanthous, Sara Strzok, Farrah Pompilus, Stefan Cano, Patrick Marquis, Stanley Cohan, Myla D Goldman, Kiren Kresa-Reahl, Jennifer Petrillo, Carmen Castrillo-Viguera, Diego Cadavid, and Shih-Yin Chen
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)., Stanley L Cohan, Harold Moses, Jonathan Calkwood, Carlo Tornatore, Chris LaGanke, Kyle E Smoot, Venkata Meka, Macaulay Okwuokenye, Christophe Hotermans, Jason P Mendoza, Monica K Mann, and Leslie A Meltzer
Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center., Kyle E Smoot, Kateri Spinelli, Tamela Stuchiner, Lindsay Lucas, Chiayi Chen, Lois Grote, Elizabeth Baraban, Kiren Kresa-Reahl, and Stanley Cohan
Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study., Sara Strzok, Sophie Cleanthous, Farrah Pompilus, Stefan J Cano, Patrick Marquis, Stanley Cohan, Myla D Goldman, Kiren Kresa-Reahl, Jennifer Petrillo, Carmen Castrillo-Viguera, Diego Cadavid, and Shih-Yin Chen
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS., Robert Zivadinov, Jennie Medin, Nasreen Khan, Jonathan R Korn, Niels Bergsland, Michael G Dwyer, Tanuja Chitnis, Robert T Naismith, Enrique Alvarez, Peter Kinkel, Stanley Cohan, Samuel F Hunter, Diego Silva, and Bianca Weinstock-Guttman
Submissions from 2017
Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE., Stanley Cohan, Ludwig Kappos, Gavin Giovannoni, Heinz Wiendl, Krzysztof Selmaj, Eva Kubala Havrdová, John Rose, Steven Greenberg, Glenn Phillips, Wei Ma, Ping Wang, Gabriel Lima, and Guido Sabatella
Biomarkers of Acute Stroke Etiology (BASE) Study Methodology., Edward C Jauch, Andrew D Barreto, Joseph P Broderick, Doug M Char, Brett L Cucchiara, Thomas G Devlin, Alison J Haddock, William J Hicks, Brian C Hiestand, Glen C Jickling, Jeff June, David S Liebeskind, Ted J Lowenkopf, Joseph B Miller, John O'Neill, Tim L Schoonover, Frank R Sharp, and W Frank Peacock
